Newsbenzinga
United Therapeutics Acquires Thymmune Therapeutics For $140M In Cash, Plus Up To $160M In Milestone-Based Earn-Outs Through 2031
· Published
Article summary
United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held, preclinical stage biotechnology company developing scalable, regenerative thymic
An excerpt from the original article.
Comments —
Loading comments…